Update on ropinirole in the treatment of Parkinson&amp;rsquo;s disease

Shill, Holly A.; Stacy, Mark

doi:10.2147/ndt.s3237

Cited by 14 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the past several decades to the present time, the most preferred therapeutic strategy in PD is to raise the level of dopamine in NCP by an exogenous supply of its precursor levodopa (L-DOPA). , Besides, DA-receptor agonists (e.g., bromocriptine, ropinirole, pergolide, pramipexole, etc. ), ,, MAO-B inhibitors (e.g., selegiline and rasagiline), , and COMT inhibitors (e.g., entacapone and tolcapone) have the potential to keep a raised level of dopamine in the brain and hence are recommended as adjunctive to L-DOPA therapy. Preclinical and clinical studies provided evidence of immense therapeutic benefits of neurotrophins (BDNF and GDNF), , antioxidants (vitamin E, CoQ10, mitoQ), ,, anti-inflammatory drugs (dexamethasone, ibuprofen, celecoxib, minocycline), − α-synuclein inhibitors (anti-α-synuclein ASO, shRNA, aptamer, NPT200-11), ,− and compounds targeting the lysosome–proteosome dysfunction (ambroxol, nilotinib, Hsp therapy, beclin, and parkin gene therapy) − in exhibiting anti-PD effects.…”

Section: Present Day Anti-pd Therapeutic Considerations and Their Lim...mentioning

confidence: 99%

“…Nanovesicular technology has further been explored in delivering both the ergot-derived (bromocriptine, pergolide, carbegoline, and lisuride) and non-ergoline (pramipexole, ropinirole, and apomorphine) dopamine receptor agonists. ,, This carrier-aided delivery has been adopted to counter the low BBB permeability and bioavailability of the agonists and reduce the occurrence of their allied side effects. , Administration of bromocriptine-encapsulated niosomes in PD rats resulted in prolonged drug release, remarkable bioavailability of the drug in the brain, reduced oxidative stress, and enhanced motor functions of the animals in comparison to free bromocriptine administration . The study further demonstrated that niosome administration did not lead to any toxicity or histopathology in the treated animals.…”

Section: Advances Made In Pd Treatment Strategies With the Assistance...mentioning

confidence: 99%

“…11,87 Besides, DA-receptor agonists (e.g., bromocriptine, ropinirole, pergolide, pramipexole, etc. ), 12,88,89 MAO-B inhibitors (e.g., selegiline and rasagiline), 13,90 and COMT inhibitors (e.g., entacapone and tolcapone) 91 have the potential to keep a raised level of dopamine in the brain and hence are recommended as adjunctive to L-DOPA therapy. Preclinical and clinical studies provided evidence of immense therapeutic benefits of neurotrophins (BDNF and GDNF), 16,92 antioxidants (vitamin E, CoQ10, mitoQ), 14,93,94 anti-inflammatory drugs (dexamethasone, ibuprofen, celecoxib, minocycline), 95−98 19,20,87,91 For instance, chronic exposure to L-DOPA, DA agonists, inhibitors of MAO-B, and COMT leads to nausea, vomiting, hallucinations, insomnia, and most significantly on−off motor fluctuations 87,110,111 (Figure 2).…”

Section: Present Day Anti-pd Therapeutic Considerations and Their Lim...mentioning

confidence: 99%

See 2 more Smart Citations

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Roy

Paul²,

Bhattacharya

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Parkinson's disease (PD) is characterized by dopaminergic neurodegeneration, resulting in dopamine depletion and motor behavior deficits. Since the discovery of L-DOPA, it has been the most prescribed drug for symptomatic relief in PD, whose prolonged use, however, causes undesirable motor fluctuations like dyskinesia and dystonia. Further, therapeutics targeting the pathological hallmarks of PD including αsynuclein aggregation, oxidative stress, neuroinflammation, and autophagy impairment have also been developed, yet PD treatment is a largely unmet success. The inception of the nanovesicle-based drug delivery approach over the past few decades brings add-on advantages to the therapeutic strategies for PD treatment in which nanovesicles (basically phospholipid-containing artificial structures) are used to load and deliver drugs to the target site of the body. The present review narrates the characteristic features of nanovesicles including their blood−brain barrier permeability and ability to reach dopaminergic neurons of the brain and finally discusses the current status of this technology in the treatment of PD. From the review, it becomes evident that with the assistance of nanovesicle technology, the therapeutic efficacy of anti-PD pharmaceuticals, phyto-compounds, as well as that of nucleic acids targeting α-synuclein aggregation gained a significant increment. Furthermore, owing to the multiple drug-carrying abilities of nanovesicles, combination therapy targeting multiple pathogenic events of PD has also found success in preclinical studies and will plausibly lead to effective treatment strategies in the near future.

show abstract

Section: Present Day Anti-pd Therapeutic Considerations and Their Lim...mentioning

confidence: 99%

Section: Advances Made In Pd Treatment Strategies With the Assistance...mentioning

confidence: 99%

Section: Present Day Anti-pd Therapeutic Considerations and Their Lim...mentioning

confidence: 99%

See 1 more Smart Citation

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Roy

Paul²,

Bhattacharya

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Levodopa rapidly gets metabolized, and the combination of levodopa along with some adjunct drugs such as carbidopa and entacapone is used to prevent its rapid metabolism in the plasma. However, the longstanding combination treatment of levodopa and carbidopa also causes several side effects. , For this purpose, ropinirole, bromocriptine, pergolide, cabergoline, and pramipexole (PPX) are used as a first-line treatment with or without levodopa to prevent the symptoms of PD. , …”

Section: Introductionmentioning

confidence: 99%

Polyvinylpyrrolidone-Capped Copper Oxide Nanoparticles-Anchored Pramipexole Attenuates the Rotenone-Induced Phenotypes in a Drosophila Parkinson’s Disease Model

Hanumanthappa,

Venugopal,

P C

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive, age-related neurodegenerative disease. The disease is characterized by the loss of dopaminergic neurons in the substantia nigra, pars compacta of the midbrain. Pramipexole (PPX) is a novel drug used for the treatment of PD. It has a high affinity for the dopamine (DA) D2 receptor subfamily and acts as a targeted mitochondrial antioxidant. It is less effective in the treatment of PD due to its short half-life, highly inconvenient dosing schedule, and long-term side effects. In recent years, PPX-loaded nanoformulations have been actively reported to overcome these limitations. In the current study, we focused on increasing the effectiveness of PPX by minimizing the dosing frequency and improving the treatment strategy for PD. Herein, we report the synthesis of biodegradable polyvinylpyrrolidone (PVP)-capped copper oxide nanoparticles (PVP–CuO NPs), followed by PPX anchoring on the surface of the PVP–CuO NPs (PPX–PVP–CuO NC), in a simple and inexpensive method. The newly formulated PPX–PVP–CuO NC complex was analyzed for its chemical and physical properties. The PPX–PVP–CuO NC was tested to protect against rotenone (RT)-induced toxicity in the Drosophila PD model. The in vivo studies using the RT-induced Drosophila PD model showed significant changes in negative geotaxis behavior and the level of DA and acetylcholinesterase. In addition, oxidative stress markers such as glutathione- S -transferase, total glutathione, thiobarbituric acid reactive species, and protein carbonyl content showed significant amelioration. The positive changes of PPX–PVP–CuO NC treatment in behavior, neurotransmitter level, and antioxidant level suggest its potential role in mitigating the PD phenotype. The formulation can be used for treatment or pharmacological intervention against PD.

show abstract

“…Dopamine levels, polymorphisms in dopamine receptor and transporter genes, and differential methylation of dopamineassociated genes are related to novelty-seeking and exploratory behavior in mammals and birds (Schinka et al, 2002;Fidler et al, 2007;Egan et al, 2009;Filby et al, 2010;van Oers and Mueller, 2010;Shaw and Øverli, 2012;Caramaschi et al, 2013;Carere and Maestripieri, 2013;Holtmann et al, 2016;Abbey-Lee et al, 2018a). Ropinirole, prescribed to treat restless leg syndrome and Parkinson's disease (Connolly and Lang, 2014), is a dopamine agonist at D2 and D3 dopamine receptors (Shill and Stacy, 2009). Importantly, research suggests that the monoamine systems are not fully independent, with many chemicals that can alter behavior having affinities for both serotonin and dopamine receptors (Bischoff et al, 1986;Lejeune and Millan, 1998;Lawler et al, 1999;Borroto-Escuela et al, 2010;Martínez-Clemente et al, 2012;de Bartolomeis et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Effects of monoamine manipulations on the personality and gene expression of three-spined sticklebacks

Abbey-Lee

Kreshchenko

Sala

et al. 2019

Journal of Experimental Biology

View full text Add to dashboard Cite

Among-individual behavioral differences (i.e. animal personality) are commonly observed across taxa, although the underlying, causal mechanisms of such differences are poorly understood. Animal personality has been correlated with physiological functions as well as fitness-related traits. Variation in many aspects of monoamine systems, such as metabolite levels and gene polymorphisms, has been linked to behavioral variation. Therefore, here we experimentally investigated the potential role of monoamines in explaining individual variation in personality, using two common pharmaceuticals that respectively alter the levels of serotonin and dopamine in the brain: fluoxetine and ropinirole. We exposed threespined sticklebacks, a species that shows animal personality, to either chemical alone or to a combination of the two chemicals, for 18 days. During the experiment, fish were assayed at four time points for the following personality traits: exploration, boldness, aggression and sociability. To quantify brain gene expression on short-and longer-term scales, fish were sampled at two time points. Our results show that monoamine manipulations influence fish behavior. Specifically, fish exposed to either fluoxetine or ropinirole were significantly bolder, and fish exposed to the two chemicals together tended to be bolder than control fish. Our monoamine manipulations did not alter the gene expression of monoamine or stress-associated neurotransmitter genes, but control, untreated fish showed covariation between gene expression and behavior. Specifically, exploration and boldness were predicted by genes in the dopaminergic, serotonergic and stress pathways, and sociability was predicted by genes in the dopaminergic and stress pathways. These results add further support to the links between monoaminergic systems and personality, and show that exposure to monoamines can causally alter animal personality.

show abstract

Update on ropinirole in the treatment of Parkinson’s disease

Cited by 14 publications

References 25 publications

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Polyvinylpyrrolidone-Capped Copper Oxide Nanoparticles-Anchored Pramipexole Attenuates the Rotenone-Induced Phenotypes in a Drosophila Parkinson’s Disease Model

Effects of monoamine manipulations on the personality and gene expression of three-spined sticklebacks

Contact Info

Product

Resources

About